DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

LH·Labcorp Holdings Inc.

$.
-. (-.%)
After Hours
High
$265.00
Open
$261.15
Market Cap
21.32B
52W High
$293.72
Low
$256.46
P. Close
$258.43
P/E
22.64
52W Low
$239.75
Fwd P/E
54.04
Mean Target
$310.12
Technical Score (1D)
36
SELL
News Sentiment
70
BULLISH
Labcorp Holdings (LH) has seen a significant upgrade to a Zacks Rank #2 (Buy), driven by positive earnings estimate revisions and growing optimism about its earnings prospects. This development suggests a potentially favorable shift in the company's outlook, which historically correlates with near-term stock price movements. Concurrently, Labcorp has advanced its digital health strategy through an expanded collaboration with Epic, integrating its full test menu into Epic's Aura platform to streamline lab ordering for healthcare systems. Further bolstering its digital health ambitions, Labcorp launched MyLabcorp™, an AI-powered mobile application utilizing OpenAI models to offer personalized explanations of lab results and health education. These initiatives underscore Labcorp's strategic focus on leveraging technology to enhance both clinician workflows and patient engagement. The company is also benefiting from expansion in specialty testing and strategic acquisitions, alongside AI integration to improve margins and customer experience. Despite these positive developments, currency fluctuations and broader macroeconomic pressures present ongoing risks to its financial performance. Investors should monitor analyst commentary for specific reasons behind the current optimistic sentiment, which contrasts with the stock's underperformance over the past year. Looking ahead, the company's focus on high-growth areas like oncology and neurology, coupled with its AI integration, will be key to watch. Additionally, Labcorp is set to go ex-dividend in four days, with a payment of $0.72 per share, continuing its dividend distribution track record.
Earnings Summary
Labcorp Holdings Inc. is a prominent provider of comprehensive laboratory services, operating within the Healthcare sector's Diagnostics & Research industry. The company offers a wide spectrum of diagnostic testing and supports the biopharmaceutical industry with drug development and medical device testing services, serving healthcare providers, pharmaceutical companies, and managed care organizations. In its most recent reported quarters, Labcorp demonstrated a positive earnings trend, with Q1 2026 EPS of $4.25 exceeding the estimate of $4.2163, and Q4 2025 EPS of $4.07 surpassing the estimate of $3.94198. This follows a pattern of consistent EPS beats in the preceding quarters, including Q3 2025 ($4.18 actual vs. $4.13813 estimate) and Q2 2025 ($4.35 actual vs. $4.17917 estimate). Revenue trends also show growth, with Q1 2026 actual revenue at $3.5376 billion compared to an estimate of $3.60999 billion, and Q4 2025 actual revenue of $3.5158 billion against an estimate of $3.55816 billion, indicating a generally upward trajectory in top-line performance. Historically, Labcorp has shown a strong ability to meet or exceed analyst expectations for earnings per share, with a beat in the last four reported quarters for which actual EPS data is available. Revenue figures, while sometimes showing a slight miss against estimates in the most recent quarters, have generally trended upwards year-over-year. Recent news highlights Labcorp's strategic initiatives, including the launch of its AI-powered mobile application, MyLabcorp™, aimed at enhancing consumer understanding of lab results and health trends, and the deeper integration of its full test menu with Epic's Aura platform to streamline clinical workflows for providers. These developments, coupled with favorable demographic trends and a projected expansion in the drug screening market, suggest a focus on patient engagement and operational efficiency. Investors will be watching for continued positive momentum from these new platforms and integrations, as well as the company's ability to translate these initiatives into sustained revenue growth and earnings performance in upcoming quarters.

EPS

EstBeatMiss
$3.58$3.92$4.26$4.60$4.94Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.78 - -
Q1'26$4.22$4.25+0.8%
Q4'25$3.94$4.07+3.2%
Q3'25$4.14$4.18+1.0%
Q2'25$4.18$4.35+4.1%
Q1'25$3.73$3.84+2.8%

Revenue

EstBeatMiss
$3.3B$3.4B$3.6B$3.7B$3.9BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.8B - -
Q1'26$3.6B$3.5B-2.0%
Q4'25$3.6B$3.5B-1.2%
Q3'25 - $3.6B -
Q2'25 - $3.5B -
Q1'25 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LH Stock Snapshot

LH is currently trading at $258.45, giving Labcorp Holdings Inc. a market cap of 21.32B and a P/E ratio of 22.6. Today's range spans $256.46–$265.00, with shares opening at $261.15 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 70/100.

Over the past year LH has traded between $239.75 and $293.72 - the current price is +7.8% off the 52-week low and -12.0% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $310.12 (range $270.00–$340.00), implying upside of +20.0%.

Volatility for LH is compressed - a HOLD signal (36/100) with bullish sentiment (70/100) at $258.45 (in the lower half of its 52-week range) in a large-cap Healthcare name (21.32B market cap) is the kind of setup where realized volatility undershoots implied. The current P/E ratio stands at 22.6. Annual range: $239.75–$293.72. That compression typically resolves with a sharp directional move - the question is timing and catalyst, not direction, because HOLD signals at this scale don't stay neutral indefinitely.

Portfolio construction in Healthcare often uses large-cap names like LH as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 36/100 (HOLD) at $258.45 (in the lower half of its 52-week range) and bullish sentiment (70/100) frame the position as a catalyst play within the $239.75–$293.72 annual range rather than a directional bet.